Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2025 05:53 ET | Source: Shell plc

SHELL PLC – REPORT ON PAYMENTS TO GOVERNMENTS FOR THE YEAR 2024

Shell plc – Report on Payments to Governments for the year 2024 Basis for preparation – Report on Payments to Governments for the year 2024This Report provides a consolidated overview of the payments...
May 08, 2025 16:05 ET | Source: Senseonics Holdings, Inc.

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor...
May 02, 2025 02:00 ET | Source: Shell plc

Shell Plc 1st Quarter 2025 Unaudited Results

SHELL PLC1st QUARTER 2025 UNAUDITED RESULTS SUMMARY OF UNAUDITED RESULTSQuarters$ million Q1 2025Q4 2024Q1...
April 30, 2025 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Provides Update on FDA Type B Meeting Request

● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |...
April 09, 2025 01:00 ET | Source: Idorsia Pharmaceuticals Ltd

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension...
March 31, 2025 08:00 ET | Source: Amarin Corporation plc

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of...
March 19, 2025 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Update for Discussion with the FDA

● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV:...
March 03, 2025 16:05 ET | Source: Senseonics Holdings, Inc.

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to...
February 27, 2025 09:00 ET | Source: Amarin Corporation plc

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with...
February 24, 2025 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Commences Gout Program NDA Discussions with the FDA

● Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV:...